Anti-Biofilm Shampoo Consumer Product
Kane Biotech Reports Positive Results from Anti-Biofilm Shampoo Consumer Product
Kane Biotech Inc today announced positive results from a consumer product test evaluating the efficacy of its shampoo on dermatitis and dandruff.
Kane Biotech’s shampoo was developed based on research indicating that the persistence of microbial biofilm may be linked with aggravating the symptoms associated with atopic dermatitis, seborrheic dermatitis (also known as eczema) and dandruff. The shampoo consists of coactiv+TM, a patented anti-biofilm formulation, and contains ingredients approved as safe for human use.
The Company launched the consumer product test in December 2019 and sent 800 shampoo samples to individuals across Canada. Based on the consumer product test questionnaire, 82% of individuals reported an overall improvement in their condition, with a reduction of dandruff, irritation, redness and itchiness symptoms.
“Having spent 25 years as a research fellow at one of the largest consumer goods companies in the world, I know that these consumer test results, which were obtained on an unoptimized product, clearly represent a major opportunity for individuals with scalp conditions,” stated Dr Gordon Guay, Kane’s Chief Scientific Officer.
“We are delighted with the overwhelmingly positive results of our shampoo consumer product test and we are looking forward to launching the product in Canada in the coming weeks, and in the U.S. later this year,” said Marc Edwards, President and Chief Executive Officer of Kane Biotech. “Nearly 1,500 individuals signed up to participate in the test, which far exceeded our expectations. We believe this indicates a gap in the market for efficacious products for these scalp conditions, and our results clearly indicate we can fill that gap for many people.
Having received numerous requests for other products containing our patented anti-biofilm formulation, we also plan to develop scalp detoxifier, conditioner and face wash formulations, in addition to our shampoo.”
Kane Biotech plans to offer the shampoo via online direct-to-consumer sales beginning in the third quarter of 2020. The Company will provide an update once the shampoo is available, including the website where it may be purchased. Kane will be applying to the Government of Canada’s CanExport SMEs program to support some of the marketing costs associated with the U.S. launch.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Company has a portfolio of biotechnologies, intellectual property (57 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, silkstem™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc.
The Company is listed on the TSX Venture Exchange under the symbol “KNE.”
Kane Biotech Reports Positive Results from Anti-Biofilm Shampoo Consumer Product
Previous Posts
